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Purpose: The NLRP3 inﬂammasome activation has been proposed as a common
mechanism for some adjuvants to boost the immune system, and cationic liposomes
were reported to potentially activate the NLRP3 inﬂammasome. Herein, we questioned
whether the NLRP3 inﬂammasome-activating cationic liposomes could promote antigen
presentation and be applied as an immune adjuvant. In addition, we aimed to investigate
the structure effect of lipid on triggering these immune responses.
Materials and methods: A series of structurally similar lipids, consisting of arginine (Arg)
head group and varied lengths of alkyl chains or spacers in between were used to prepare
cationic liposomes. Lipopolysaccharide-primed human or murine macrophages or phorbol
12-myristate 13-acetate-primed THP-1 cells were treated with these liposomes, and inter-
leukin (IL)-1β secretion was measured to quantify the NLRP3 inﬂammasome activation.
Lysosome rupture was examined in THP-1 cells by the ﬂuorescence loss of acridine orange,
a lysosome dye. Further, chicken ovalbumin (OVA) was loaded on the liposome surface and
applied to murine bone marrow-derived dendritic cells (BMDCs), which activate OT-I and
OT-II lymphocytes upon major histocompatibility complex (MHC) class I- and class II-
mediated antigen presentation, respectively. OT-I and OT-II cell division and IL-2 secretion
were measured to evaluate the antigen presentation efﬁciency. The expressions of MHC
molecules and co-stimulatory molecules ie, CD80, CD86, and CD40 on BMDCs were
investigated by ﬂow cytometry.
Results: All the liposomes showed size distributions of 80–200 nm and zeta potentials of
around 50 mV. A3C14 liposomes, consisting of Arg-C3-Glu2C14 lipids induced the most
potent lysosome rupture and NLRP3 inﬂammasome activation. OVA-A3C14 also exhibited
the most potent MHC class I- and class II-mediated antigen presentation in BMDCs without
interfering MHC and co-stimulatory molecules.
Conclusion: The hydrophobic moieties of arginine-based liposomes are crucial in stimulat-
ing innate immune cells. A3C14 liposomes were non-immunogenic but strongly activated
innate immune cells and promoted antigen presentation, and therefore can be applied as
immune adjuvants.
Keywords: arginine, cationic liposomes, NLRP3 inﬂammasome activation, antigen
presentation, lysosome rupture
Introduction
Cationic liposomes are widely used for protein delivery and gene transfection due
to their electrostatic interaction with negatively charged macromolecules. To date,
many attempts on modifying the structures of cationic lipids have been accumulated
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to enhance their drug delivery efﬁciency and meanwhile
hurdle the toxicity.1–3 However, recent ﬁndings have
shown that some cationic liposomes could cause the
NLRP3 inﬂammasome activation in macrophages,4–6
revealing a potential of these liposomes being applied as
immune stimuli.
The NOD-like receptors (NLRs) are intracellular sen-
sors of invading microbes and “danger” molecules that are
derived from the hosts such as ATP. The NLRP3 inﬂam-
masome is a multiprotein assembly of NLR-family protein
NLRP3, pro-caspase-1, and an apoptosis-associated speck-
like protein containing a CARD (ASC) adaptor, which is
formed upon activation. It is crucial for innate immunity to
trigger the release of pro-inﬂammatory cytokines such as
interleukin (IL)-1β, and two sequential signals are needed
for its secretion: one is the activation of toll-like receptor
(TLR) such as TLR4, which accelerates the production of
pro-IL-1β, and the other is the NLRP3 inﬂammasome
activation, which activates caspase-1 to process pro-
IL-1β into its matured form IL-1β. Hitherto knowledge
regarding the molecular mechanism of the NLRP3 inﬂam-
masome activation proposes the involvement of reactive
oxygen species (ROS) and/or lysosomal components
released into cytosol upon phagolysosome rupture.7
Charged nanoparticles, in particular, cationic composi-
tions, might induce the NLRP3 inﬂammasome activation
through phagolysosome membrane destabilization follow-
ing the phagoendocytosis,6 well-known example of which
includes conventional adjuvant alum, QuilA, and chitosan
particles.8,9 The released IL-1β recruits other immune cells
to the site so that the immune responses can be ampliﬁed.
Accordingly, the NLRP3 inﬂammasome activation is cri-
tical for these adjuvants to elicit immunological effects.
Upon the activation of the innate immune system, adap-
tive immune responses can be triggered through efﬁcient
antigen presentation by antigen presenting cells (APCs)
such as dendritic cells (DCs) to activate T cells. There are
mainly two pathways regarding the antigen presentation:
major histocompatibility complex (MHC) class I molecules-
mediated antigen presentation, which is recognized by the
T cell receptor (TCR) on immature CD8+ T cell surface and
promotes the maturation of CD8+ T cells (cytotoxic T cells,
CTLs); and MHC class II molecules-mediated antigen pre-
sentation, which activates CD4+ T cells (T helper cells, Th).
The activation of T cells results in the cell division as well as
the secretion of IL-2, which further drives the proliferation
and differentiation of T cells. In addition to TCR signaling,
binding of co-stimulatory molecules is also synchronized to
fully activate T cells. For example, CD80/CD86 recognizes
CD28, and CD40 recognizes CD40-L on T cells. Deﬁcient
expression or recognition of co-stimulatory molecules on
APCs will otherwise compromise the T cell activation.
Herein, we report an investigation of a series of struc-
turally similar arginine-based cationic liposomes on the
NLRP3 inﬂammasome activation in macrophages, as
well as their potential application as antigen carriers and
adjuvants in terms of antigen delivery to bone marrow-
derived dendritic cells (BMDCs). MHC class I- and class
II-mediated antigen presentations were studied by examin-
ing the secretion of IL-2 and proliferations of OT-I
(OVA257–264 recognizing CD8
+) and OT-II (OVA323–339
recognizing CD4+) T cells, respectively. Lysosome rupture
induced by cationic liposomes was studied by ﬂow cyto-
metry, and the expressions of MHC and co-stimulatory
molecules on BMDCs were evaluated after treatment
with naked liposomes.
Material and methods
Reagents, antibodies, and mice
The following reagents were purchased: phorbol
12-myristate 13-acetate (PMA) and chicken ovalbumin
(OVA) from Sigma–Aldrich; OVA conjugated with Alexa
Fluor® 555 (OVA555) from Thermo Fisher Scientiﬁc;
acridine orange (AO) from Dojindo Laboratories; adeno-
sine 5′-triphosphate disodium salt hydrate (ATP) from
TCI; lipopolysaccharide (LPS) Escherichia coli (E. coli)
O111:B4 from InvivoGen; NLRP3 inhibitor CP-456773
(also known as CRID3) from Pﬁzer Inc; Caspase-1 inhi-
bitor VX765 from Selleck Chemicals LLC;
FITC-conjugated anti-mouse CD86 mAb (clone PO3)
from Serotec; PE-conjugated anti-mouse MHC-I (H-2Db)
mAb (clone 28-14-8), FITC-conjugated anti-mouse
MHC-I (H-2Kb) mAb (clone AF6-88.5.5.3), eFluor® 450-
conjugated anti-mouse CD80 mAb (clone 16-10A1), PE-
conjugated anti-mouse CD40 mAb (clone 1C10) and
PerCP/Cy5.5-conjugated anti-mouse CD11c mAb (clone
N418) from eBioscience; and PerCP/Cy5.5-conjugated
MHC-II (I-A/I-E) anti-mouse mAb (clone AF6-120.1)
from BioLegend. Arginine-containing cationic lipids
were synthesized according to the previous research.1–3
The cationic lipids were named according to the chemical
structure, where Arg indicates the lipids with an arginine
head group; the number in the middle indicates the carbon
number of the spacers, and the last number indicates the
carbon number of the alkyl chains (Figure 1).
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C57BL/6, OT-II, and OT-I/RAG2-KO mice (female,
8–12 weeks old) were bred under speciﬁc pathogen-free
conditions, and the experiments were carried out at the
University of Bonn in compliance with institutional guide-
lines and the German law for Welfare of Laboratory
Animals.
Cell culture
Human peripheral blood mononuclear cells were isolated
from the buffy coat of healthy donors at University Hospital
Bonn after written consent was given in accordance with the
Declaration ofHelsinki, and the protocolwas approved by the
Institutional Review Board at University of Bonn. Positive
selection of monocytes by CD14 MicroBeads (Miltenyi
Biotec) was performed, followed by differentiation into
macrophages using GM-CSF.6 These cells were cultured in
RPMI1640 medium (Gibco®, Life Technologies) supple-
mented with 10% fetal calf serum (FCS) and 1% penicillin-
streptomycin (PS) at 37°C under 5% CO2 atmosphere.
Human macrophages (2.5×105/mL) were primed with 1 ng/
mL LPS for 2 hrs before being treated with liposomes.
Immortalized murine macrophages were cultured in
DMEM medium (Gibco®, Life Technologies) supplemen-
ted with 10% FCS and 1% PS at 37°C under 5% CO2
atmosphere. These cells (1.0×105/well) were seeded in 96-
well plate and primed with 100 ng/mL LPS for 2 hrs
before use.
Human leukemic THP-1 monocytes obtained from
JCRB Cell Bank, Osaka, Japan were cultured in
RPMI1640 medium supplemented with 10% fetal bovine
serum and 1% PS at 37°C under 5% CO2 atmosphere.
THP-1 cells (4×105/mL) were primed with 100 nM PMA
for 18 hrs before use. Then, the cells became adherent and
the excess PMA was washed off thrice using pre-warmed
Dulbecco’s Phosphate-Buffered Saline .
BMDCs were generated according to the reported
protocol.10 Brieﬂy, bone marrow of mice (C57BL/6) was
isolated by ﬂushing the hind limbs with PBS. Extracted
cells were re-suspended and ﬁltered through a 40 μm cell
strainer. After centrifugation at 300×g for 5 mins, cells
were re-suspended in BMDC culture medium, which was
made from Iscove’s Modiﬁed Dulbecco’s Medium, 10%
FCS, 2.5% GM-CSF-containing J558L cell culture super-
natant, 50 μM beta-mercaptoethanol, 100 U/mL penicillin,
and 0.1 mg/mL streptomycin. Cells were cultured in 10 cm
petri dishes at 37°C under 5% CO2 atmosphere for 3 days.
Then, all the cells were harvested, centrifuged,
re-suspended in fresh BMDC culture medium, and cul-
tured in 10 cm petri dishes for 7–8 days before use.
OT-I and OT-II cells were collected from the spleen of
OT-I/RAG2-KO and OT-II mice, respectively. Brieﬂy, the
spleen was homogenized in PBS and ﬁltered through
a metal mesh. After centrifugation at 1,500 rpm for
10 mins at 4°C, cells were resuspended in 2 mL of red
blood cell lysis buffer and incubated for 5 mins at room
temperature (rt). Then, 8 mL of PBS was added, and cells
were ﬁltered through 100 μm mesh and centrifuged at
1,500 rpm for 10 mins at 4°C. The cells were resuspended
in T cell culture medium (RPMI medium containing 10%
FCS and 1% PS) before use.
Preparation of cationic liposomes and
loading with antigens
The cationic liposomes were prepared by hydration and
bath-type sonication as previously reported.6 The lipid
powder Arg-C0-Glu2C14, Arg-C3-Glu2C14, Arg-C5-Glu
2C14, Arg-C7-Glu2C14, Arg-C0-Glu2C16, or Arg-C0-
Glu2C18 was employed to fabricate A0C14, A3C14,
A5C14, A7C14, A0C16, or A0C18 liposomes in 20 mM
HEPES buffer, respectively. The liposome dispersions
HN
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O
O
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Figure 1 Chemical structures of the arginine-containing cationic lipids. n indicates the carbon number of the alkyl chains, and x indicates the carbon number of the spacers
between the hydrophilic and hydrophobic parts.
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were stored at 4°C and homogenized by a vortex mixer for
10 s or re-suspended using a bath-type sonicator for 2–5
mins before use.
Antigen (ie, OVA)-loaded liposomes were freshly
made by mixing soluble OVA and liposomes in HEPES
buffer and standing at rt for 5 mins. Then, the resulting
complex as well as the same volume of HEPES buffer
(used for control groups) was diluted in culture medium
and added to cells instantly.
Characterization of arginine-containing
cationic liposomes
A dynamic laser scattering (DLS) spectrophotometer (N4
PLUS Submicro Particle Size Analyzer, Beckman Coulter)
and a Zetasizer Nano S90 (Malvern Instruments) were
employed to measure the particle diameter and zeta poten-
tial, respectively. Repeated measurements (n=3) were per-
formed by using a dilution of cationic liposome dispersion
containing 5 μg/mL lipids in 1 mL of HEPES buffer.
The NLRP3 inﬂammasome activation
Primed human or murine macrophages or THP-1 cells were
exposed to a 100 μM (ﬁnal concentration, fc) liposome-
containing culture medium at 37°C for 18 hrs incubation and
the supernatants were collected for ELISA tests (DuoSet®,
R&DSystems) as previously reported.6 1 mMATPwas added
1 hr before the cytokine detection as a positive control. For
inhibition assays, NLRP3 inhibitor CP-456773 (fc: 5 μM) or
casp-1 inhibitor VX765 (fc: 25 μM)was added to primed cells
2 hrs prior to the addition of liposomes. Silica (fc: 400 μg/mL)
was used as a positive control and kept with cells for 20 hrs.
The secretion of IL-1ß was detected by homogenous time-
resolved ﬂuorescence and the inhibition rate was calculated
according to equation (1):
Inhibition rate = (1- [IL-1ß]inhibitor + liposomes /[IL-1ß]liposomes)
× 100% (1)
where [IL-1ß]liposomes indicates the concentration of IL-1ß
released to the supernatant after treatment with liposomes,
and [IL-1ß]inhibitor + liposomes indicates the concentration of
IL-1ß released to the supernatant after treatment with each
inhibitor and liposomes.
Lysosome rupture assay
AO was used to label and examine the rupture of
lysosomes.11 Brieﬂy, primed THP-1 cells were treated with
5 μg/mL AO for 15 mins at 37°C, followed by washing and
overnight incubation with 100 μM liposomes. The cell popu-
lation with AO ﬂuorescence loss was gated and recorded
using ﬂow cytometry (FACSAria II Cell Sorter, BD
Biosciences). The signals from AO-labeled and non-labeled
THP-1 cells without exposure to liposomes were gated to
reﬂect intact lysosomes and total lysosome loss, respectively.
Antigen uptake in BMDCs
BMDCs (1.6×105/well) were seeded in a 48-well cell culture
plate for 2 hrs adhesion. Then, the culture medium was
exchanged to that containing OVA555 (fc: 2.5 μg/mL)-
loaded cationic liposomes (fc: 25 μM) and incubated with
BMDCs for 2 hrs. After washing off twice with PBS, the
cells were detached from the plate by Trypsin-EDTA, and the
amount of internalized OVA was measured by the ﬂuores-
cence intensity of Alexa Fluor® 555 using ﬂow cytometry.
T cell activation and proliferation
BMDCs (7.5×104 cells/well) were seeded in a 96-well cell
culture plate for 2 hrs adhesion prior to medium exchange
with that containing OVA (fc: 25 μg/mL)-loaded cationic
liposomes (fc: 25 μM). Likewise, free OVA without lipo-
somal association and naked liposomes were added to the
BMDCs culture plate as controls. The OVAwas allowed to
be internalized by BMDCs for 2 hrs. To label the spleno-
cytes of mice, 1 μM carboxyﬂuorescein succinimidyl ester
(CFSE) was used for 15 mins incubation at 37°C. The
labeling was stopped with ice-cold PBS and washed off
thrice with PBS by centrifugation at 1,500 rpm for 10
mins at 4°C. Then, BDMCs were washed twice with
PBS and CF-labeled splenocytes from OT-I mice
(1.25×105/well) or CF-labeled splenocytes from OT-II
mice (1.6×105/well) were added into the BMDC culture
plate. The supernatants were partially collected after over-
night incubation for ELISA assay (ie, IL-2). After 48 hrs
incubation, the cells were collected for ﬂow cytometric
analysis. OT-I cells and OT-II cells were gated by using
anti-CD8 or anti-CD4 mAb, respectively. The T cell pro-
liferation was evaluated by CF ﬂuorescence intensity, and
the average number of cell divisions (ie, division index, D.
I.) was calculated using the formula (2):
D:I: ¼ ∑
i
0 i Ni2i
∑i0
Ni
2i
(2)
where i is the generation number (0 indicates the undi-
vided cell population), and Ni is the cell number of gen-
eration i.
Li et al Dovepress
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Expression of activation markers on
BMDCs
BMDCs (4.5×105 cells/well) were seeded in a 24-well cell
culture plate for 2 hrs adhesion. Then, 50 μM (fc) of each
type of liposomes was added to the culture plate and kept
with cells for 2 hrs. After washing off the liposomes twice
with PBS, fresh culture medium was added for overnight
incubation. Finally, the cells were detached from the cul-
ture plate and stained with two cocktails of activation
markers at 4°C for 10 mins separately. One cocktail con-
tained FITC-conjugated anti-CD86 mAb, PE-conjugated
anti-MHC-I (H-2Db) mAb, and PerCP/Cy5.5-conjugated
anti-MHC-II (I-A/I-E) mAb; and the other contained
FITC-conjugated anti-MHC-I (H-2Kb), eFluor® 450-
conjugated anti-CD80 mAb and PE-conjugated anti-CD
40 mAb. After labeling, the cells were washed with PBS
thrice and analyzed by ﬂow cytometry.
Statistic analysis
Student’s t-tests were applied to examine the signiﬁcant
differences of A3C14 or A5C14 liposomes with the con-
trols or other arginine-containing cationic liposomes inde-
pendently in Figures 2, 3, 5 and 6 using Microsoft Excel.
A P-value of less than 0.05 was considered statistically
signiﬁcant.
Results
Preparation and characterization of
arginine-containing cationic liposomes
As listed in Table 1, the sizes of the cationic liposomes
could be regulated to nanometer-magnitude, ranging from
80 to 200 nm by sonication. The zeta potentials, which
reﬂect the surface electronic property of nanoparticles are
basically determined by the head group of the composing
lipids facing the aqueous environment. Because the head
groups of these lipids are the same arginine group, similar
zeta potentials were obtained, ranging from 43 to 60 mV,
which are thought to be highly cationic to provide sufﬁ-
cient dispersion stability. To evaluate the homogeneity of
the size of liposomes, polydispersity index (PDI) was
employed to investigate the mono-dispersed state of the
liposomes, the values of which varied from 0.15 to 0.22. In
the DLS analysis, a single sharp peak was also observed
for all the liposomes (Figure S1), indicating the mono-
dispersed property of the liposomes. However, during long
time storage (eg, one month) at 4°C, large aggregations of
A0C14 liposomes (>1 μm) were frequently observed. In
this case, it was difﬁcult to acquire the liposome dispersion
with the original size. Other liposomes were relatively
stable during storage at least for one month, and the
sizes could keep consistent after simple vortex or bath-
type sonication shortly.
The NLRP3 inﬂammasome activation
As shown in Figure 2, A3C14 and A5C14 liposomes
induced a signiﬁcantly stronger release of IL-1β than all
the other tested liposomes in both human and murine
macrophages; while in THP-1 cells, A3C14 liposomes
were the most potent to trigger IL-1β release. Decreasing
the liposome concentration from 100 μM to 50 μM
resulted in remarkably decreased secretion of IL-1β
(Figure 2A). Thus, the NLRP3 inﬂammasome activation
by arginine-containing cationic liposomes was concentra-
tion-dependent. However, none of these liposomes could
trigger IL-1β release in unprimed immune cells (data not
shown). Although the human macrophages from different
donors may exhibit different sensitivities to liposomes,
A3C14 liposomes were always the most potent to activate
the NLRP3 inﬂammasome, followed by A5C14 lipo-
somes; and the inhibitors of NLRP3 and casp-1 led to
55–75% decrease of IL-1β release in A3C14 and A5C14
liposome-treated cells (Figures 2D and S2). On the other
hand, the secretion of other cytokines such as TNF-α and
IL-6 was not largely inﬂuenced upon liposome exposure
(Figure S3), thereby indicating that the IL-1β release
caused by these liposomes depends on the NLRP3 inﬂam-
masome activation. Because higher concentrations (>100
μM, data not shown) or longer exposure periods (eg, 48
hrs, Figure S4) of liposomes caused severe death of
macrophages and monocytes at least partially due to the
pyroptosis induced by casp-1 activation, the condition of
liposomes applied to cells was set to 100 μM (fc) and 18
hrs incubation time as maximum.
Lysosome rupture
The cellular lysosomes were labeled with AO, and the loss of
AO ﬂuorescence was acquired by ﬂow cytometry to evaluate
lysosome rupture (Figure 3A). As shown in Figure 3B,
A3C14 liposomes which triggered the most potent NLRP3
inﬂammasome activation, induced the most potent lysosome
rupture in primed THP-1 cells; ie, approximately 45% of the
cell population exhibited signiﬁcant lysosomal damage. In
comparison, A5C14 liposomes caused moderate (approxi-
mately 20%) and other liposomes performed relatively
weak (5–12%) potency of lysosome rupture.
Dovepress Li et al
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Antigen uptake in BMDCs
Assuming that the isoelectric point (pI) value of OVA is
around 4.6–4.9,12 OVA shows a negative charge at neutral
pH, allowing the loading on the surface of cationic lipo-
somes through electrostatic association. In comparison to
naked liposomes, all the OVA/liposome complexes exhib-
ited size increases of approximately 50 nm in diameter and
zeta potential decreases to 20–30 mV, indicating the fact of
OVA loading and a similar association pattern of OVA on
these cationic liposomes (Table S1).
As shown in Figure 4, the OVA uptake in BMDCs was
increased when they were loaded to A3C14, A5C14, and
A7C14 cationic liposomes. By contrast, A0C18, A0C16 or
A0C14 liposomes did not increase the cellular uptake of asso-
ciated OVA.
Antigen presentation and activation of
T cells
Antigen presented by APCs will consequently stimulate
T cells that they encounter to release IL-2. Thus, MHC-I
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Figure 2 NLRP3 inﬂammasome activation of macrophages and monocytes induced by arginine-containing cationic liposomes. LPS (1 ng/mL)-primed humanmacrophages (A), LPS
(100 ng/mL)-primed immortalized murine macrophages (B), and PMA (100 nM)-primed THP-1 cells (C) were incubated with 100 μM or 50 μM cationic liposomes for 18 hrs. The
NLRP3 inﬂammasome activation was evaluated by the release of IL-1ß using human or murine IL-1ß ELISA kit. Data show the mean + SD of three replicates; **P<0.01. (D) NLRP3
inhibitor CP-456773 and caspase-1 (casp-1) inhibitor VX765 suppressed NLRP3 inﬂammasome activation induced by A3C14 and A5C14 liposomes. 5 μM NLRP3 inhibitor CP-
456773 (also known as CRID3) or 25 μM casp-1 inhibitor VX765was added to the LPS-primed humanmacrophages prior to the addition of 100 μM liposomes. The release of IL-1β
was detected by HTRF and the inhibition rate was calculated to indicate the suppression level of IL-1β by each inhibitor. Data show the mean + SE of two independent experiments
(ie, macrophages were collected from two different donors and the measurements were performed at different days) with two replicates, respectively.
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and MHC-II mediated antigen presentations can be eval-
uated by the secretion of IL-2 from OT-I and OT-II cells,
respectively. J558L-GM-CSF derived BMDCs have been
established and used for the study of cross-presentation,20
therefore we applied these cells to study the antigen pre-
senting pathways of the liposomes. As shown in Figure 5,
liposomes alone did not lead to T cell activation. However,
OVA-associated A3C14 liposomes remarkably enhanced
IL-2 secretion in OT-I cells, whereas other OVA-liposomes
exhibited medium or slight enhancement in comparison to
that of free OVA (Figure 5A). Similarly, the promotion of
MHC-II mediated antigen presentation was also observed
in OVA-A3C14 liposomes (Figure 5B).
Furthermore, T cell proliferation was investigated to
evaluate the liposomal effect on antigen presentation.
CF-labeled OT-I and OT-II cells were gated by anti-
Figure 3 Arginine-containing cationic liposomes induced the lysosome rupture in PMA-primed THP-1 cells. Acridine orange (AO) was incubated with cells for 15 mins prior
to overnight exposure to cationic liposomes. (A) Gating strategies of THP-1 cells using ﬂow cytometry. Cells were ﬁrst gated by forward scatter (FSC)-height (H) vs side
scatter (SSC)-H, and then gated by FSC-area (A) vs FSC-H. The ﬂuorescence intensities of AO were recorded to evaluate the percentage of the cells with signiﬁcant
lysosome rupture (B). Data show the mean + SD of three independent experiments; *P<0.05.
Dovepress Li et al
International Journal of Nanomedicine 2019:14 submit your manuscript | www.dovepress.com
DovePress
3509
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
3.
9.
32
.1
67
 o
n 
18
-O
ct
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
CD8 or anti-CD4 mAb, respectively (Figure S5). The
sequentially half-decreased CF ﬂuorescence was
recorded by ﬂow cytometry to reﬂect the cells of differ-
ent generations (Figure 5C and D). Herein, mean divi-
sion times per cell (division index, D.I.) was employed
to denote the potential of T cell proliferation. As shown
in Figure 5E and F, enhanced proliferation of OT-I and
OT-II cells was observed for all the liposomes only
when they were associated with OVA. Among all the
arginine-containing cationic liposomes, OVA-A3C14
liposomes exhibited the highest D.I. values, as well as
the % of divided T cells in both MHC-I and MHC-
II mediated antigen presentation.
Inﬂuence of liposomes on the expression
of MHC and co-stimulatory molecules
The expression of co-stimulatory molecules such as CD80,
CD86, and CD40 on the surface of APCs is necessary to
efﬁciently activate T lymphocytes during antigen presenta-
tion by MHC molecules. To investigate the inﬂuence of
liposomes, the expression levels of these markers were
examined using ﬂow cytometry (see gating strategies in
Table 1 Formulation and characterization of cationic liposomes. Data show the mean ± SD (n=3)
Liposomes Composing lipids Size distribution (nm) Zeta potential (mV) PDI
A0C14 Arg-C0-Glu2C14 157.0±68.3 55.5±1.1 0.15±0.02
A3C14 Arg-C3-Glu2C14 192.8±94.7 59.3±4.5 0.18±0.02
A5C14 Arg-C5-Glu2C14 126.4±41.5 45.1±0.4 0.10±0.02
A7C14 Arg-C7-Glu2C14 79.9±31.4 51.7±1.4 0.19±0.02
A0C16 Arg-C0-Glu2C16 124.4±52.1 43.8±2.1 0.18±0.02
A0C18 Arg-C0-Glu2C18 152.9±70.6 46.7±0.7 0.22±0.01
Figure 4 Antigen delivery efﬁciency of arginine-containing cationic liposomes in BMDCs. Alexa Fluor 555-conjugated OVA (fc: 2.5 μg/mL) was freely dispersed or loaded on
cationic liposomes (fc: 25 μM), and incubated with BMDCs for 2 hrs. The extracellular OVA-liposomes were washed off, and the intracellular OVA was measured by ﬂow
cytometry. (A) Cells were ﬁrst gated by FSC-A vs SSC-A, and then gated by SSC-A vs SSC-H. (B) Representative histograms and (C) mean ﬂuorescent intensities of
intracellular OVA. Data show the mean + SD of two independent experiments with two replicates, respectively.
Abbreviations: BMDCs, bone marrow-derived dendritic cells; OVA, ovalbumin; FSC, forward scatter; SSC, side scatter; A, area; H, height.
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Figure 5 Activation of OT-I and OT-II cells through MHC-I and MHC-II mediated antigen presentation pathways, respectively. BMDCs were incubated with OVA (fc: 25 μg/mL)-loaded
cationic liposomes (fc: 25 μM) or the same concentration of solubleOVA, or the same concentration of liposomes for 2 hrs, and then extracellularOVAor liposomeswerewashed off with
DPBS. CFSE was used to label splenocytes fromOT-I mice (A,C, E) or OT-II mice (B,D, F) and then labeled cells were added into the BMDC culture plate. The supernatant was partially
collected after overnight incubation to detect the secretion of IL-2 using an ELISA kit (A,B); and the cells were collected after 48 hrs incubation to analyze theOT-I cell andOT-II cell division
usingﬂowcytometry (C,D,E,F, see gating strategies ofOT-I andOT-II cells in Figure S5). (−) Lipo indicates theBMDCswithout treatment [(−)OVA]or treatedwith solubleOVA[(+)OVA];
other experimental groups were treated with naked liposomes [(−) OVA], or OVA-loaded liposomes [(+) OVA]. Data show the mean+SD of two independent experiments with two
replicates, respectively; *P<0.05, **P<0.01.
Abbreviations: BMDCs, bone marrow-derived dendritic cells; OVA, ovalbumin; CFSE, carboxyﬂuorescein succinimidyl ester.
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Figure 6 Flow cytometry of activation markers on BMDCs. BMDCs were incubated with each type of the liposomes (fc: 50 μM) for 2 hrs and then washed off. After further
incubation overnight in the fresh culture medium, the cells were labeled with ﬂuorescent antibodies against MHC-I (H-2Db), MHC-I (H-2Kb), MHC-II (I-A/I-E), CD80, CD86, and
CD40 followed by ﬂow cytometry (A, see gating strategies in Figure S6). (B) The mean ﬂuorescent intensities were measured and data show the mean + SD of two independent
experiments with two replicates, respectively. *P<0.05, **P<0.01. Note that the liposomes were not associated with OVA. LPS was used as a positive stimulus.
Abbreviations: BMDCs, bone marrow-derived dendritic cells; LPS, lipopolysaccharide; OVA, ovalbumin.
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Figure S6). Note that BMDCs were treated with naked
liposomes without OVA loading.
As shown in Figure 6A, A3C14 liposomes did not
interfere with any of the tested markers on BMDCs,
including MHC-I and MHC-II molecules, CD80, CD86,
and CD40 co-stimulatory molecules. However, treating
with other liposomes might have inﬂuenced the expression
of these markers (Figure 6B). A resemblance of A5C14,
A7C14, A0C16, and A0C18 liposomes was observed in
the down-regulation all of the tested activation markers
except MHC-II molecules; on the contrary, A0C16 lipo-
somes ampliﬁed the expression of MHC-II molecules. For
A0C14 liposomes, MHC-II molecules and CD40 have
been up-regulated, whereas the expressions of CD80 and
CD86 were suppressed.
Discussion
Arginine-containing cationic liposomes were prepared
using a hydration of the arginine-type cationic lipid
powder followed by a bath-type sonication method as
previously reported.6 The advantage of this method is
the easy-handling and manipulation of the size of lipo-
somes by adjusting the time of sonication. Herein, all
the arginine-containing lipids could be hydrated and
sonicated for the same time. The resulting liposomes
showed similar zeta potentials but various sizes, sug-
gesting the inﬂuences of spacers and hydrophobic tails
of the composing lipids in their molecular assembling
properties. As with lysine-containing cationic lipids in
our previous report,6 increasing the length of hydropho-
bic tails of arginine-containing lipids from 14 carbons to
16 or 18 carbons or inserting a spacer (ie, 3, 5, or 7
carbons) between the head group and the hydrophobic
part, could increase the stability of the liposomes in
view of their constant size distributions after storage at
4°C for one month. Otherwise, aggregation and sedi-
mentation of the liposomes (ie, A0C14) could be
observed. Besides the surface electrostatic repulsion
among the cationic liposomes, a more stable liposome
in aqueous solution was thought to be obtained by
increasing the hydrophobicity of the bilayer, that was
strengthened enough to overcome the tendency of fusion
with each other.
Cationic liposomes can be readily internalized into
the cells and applied as protein or gene delivery
systems.1,3,13,14 To induce the NLRP3 inﬂammasome
activation, cellular internalization of the arginine-
containing cationic liposomes was indispensable
(Figure S7A). Inhibition of the endocytic pathway of
A3C14 and A5C14 liposomes such as clathrin-
mediated endocytosis would lead to a decreased
NLRP3 inﬂammasome activation (Figure S7B).
However, priming of the immune cells using LPS or
PMA was a premise to trigger IL-1β release (data not
shown), indicating the role of these liposomes as second
signals in the NLRP3 inﬂammasome activation. It is
conceivable that cationic liposomes have a high poten-
tial to fuse with anionic biomembrane via electrostatic
interaction; thereby, lysosome rupture after the endocy-
tosis/phagocytosis of cationic liposomes may occur
owing to the disruption of the membrane lipids.
Among all the tested liposomes, the strongest NLRP3
inﬂammasome activator A3C14 induced the most potent
lysosome rupture. The subsequent release of lysosomal
proteases, such as cathepsin B, was thought to trigger
the formation of NLRP3 complex and maturation of IL-
1β by caspase-1 activity.8,15 On the other hand, ROS
have also been hypothesized as an alternative upstream
signaling of NLRP3 inﬂammasome activation.7
However, the level of ROS was not increased by
A3C14 or A5C14 liposomes; on the contrary, reduced
ROS was obtained (Figure S8) and the removal of ROS
did not suppress the NLRP3 inﬂammasome activation
neither (Figure S7B). Therefore, lysosome rupture was
proposed as the pathway of NLRP3 inﬂammasome acti-
vation utilized by the tested arginine-containing cationic
liposomes, which is consistent with that of lysine-
containing cationic liposomes bearing the same hydro-
phobic moieties and spacers.6
Classically, MHC-I molecules process the endogen-
ous antigens distributed in the cytosol, whereas the
presentation of exogenous antigens is restricted to
MHC-II mediated pathway, which undergoes endocyto-
sis/phagocytosis and loads antigens derived from lyso-
somes. However, cross-presentation of the endocytosed
antigens by MHC-I molecules also occurs, leading to
the activation of CD8+ T cells.16,17 Recent evidence
has indicated that the endocytosis mechanisms of anti-
gens greatly inﬂuence the antigen presentation
pathway.18 For example, soluble antigens uptaken by
the mannose receptor (MR) tend to be routed toward
the early endosomal compartment, where a mildly
acidic environment facilitates the MHC class
I-restricted antigen presentation. In contrast,
Dovepress Li et al
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pinocytosis or scavenger receptor (SR)-mediated endo-
cytosis directs the antigens toward the lysosomal com-
partment, where MHC-II-restricted antigen presentation
takes place. Since OVA can target MR and SR,19,20 it
can be presented by both MHC-I and MHC-II mole-
cules, and similar presenting capacity through these
two routings was obtained under our experimental con-
ditions (Figure 5). Interestingly, although A3C14 lipo-
somes enhanced the total uptake of loaded OVA and
meanwhile facilitated both MHC-I and MHC-II
mediated antigen presentation, more enhanced T cell
activation and proliferation via MHC-I was observed
than that of MHC-II mediated antigen presentation.
Obviously, A3C14 liposomes altered the intracellular
routing of OVA so that they contributed to the
increased ratio of cross-presentation. OVA association
on the surface of cationic liposomes was achieved
through electrostatic interaction at a neutral pH (7.4,
HEPES buffer), and this force could be diminished at
lower pHs and eliminated when the pH drops to the
pI of OVA (4.6–4.9).12 Thus, the unloading of OVA
would gradually occur as the acidiﬁcation of endosome
compartments continues, and fully expose the cationic
liposomes at lysosomal pH. It is reasonable that A3C14
liposomes were the most capable of lysosome rupture,
thereby the release of carried antigens into cytosol
consequently endowed the antigen presentation by
MHC class I molecules.
Similar discussion has also been proposed by
Welsby et al, that adjuvant saponin QS-21 directly
activated human monocyte-derived DCs and promoted
a pro-inﬂammatory transcriptional program through
lysosomal destabilization, which contributed to its
adjuvanticity to antigens for both cellular and humoral
immune responses.21 Vaccine adjuvants such as alum
which are widely used to boost the immune response of
antigens were also reported to trigger the NLRP3
inﬂammasome activation.9,22 Although the intrinsic
relevance between NLRP3 inﬂammasome activation
and antigen presentation is still unclear, we found that
A3C14 and A5C14 liposomes, which remarkably acti-
vated NLRP3 inﬂammasome in macrophages, were also
capable to promote antigen presentation in BMDCs in
the same order of potency. Herein, we propose that
NLRP3 inﬂammasome activation can be utilized as an
indicator in the preliminary screening of similar parti-
culate adjuvants to estimate their immune activities and
adjuvanticities.
To fulﬁll the T cell activation, docking with the co-
stimulatory molecules on APCs is crucial to strengthen
and prolong the cell–cell interaction so as to efﬁciently
and speciﬁcally present the antigens to T cells. Deﬁcient
expression or recognition of these co-stimulatory mole-
cules would otherwise lead to a compromised or failed
T cell activation. In contrast to A3C14 liposomes, which
did not affect the expressions of MHC and co-stimulatory
molecules on BMDCs, A5C14, and A7C14 liposomes
decreased the expressions of CD80, CD86, and CD40
(Figure 6). Accordingly, the T cell activation was not
enhanced as much as that of A3C14 liposomes
(Figure 5) although comparable antigen delivery efﬁcien-
cies were obtained (Figure 4). However, these liposomes
could still facilitate antigen presentation in comparison to
free OVA through both MHC-I and MHC-II pathways,
indicating the importance of the amount of antigens that
have been internalized and processed by the APCs. On the
other hand, A0C16 liposomes moderately increased MHC-
II mediated antigen presentation despite their mediocre
antigen uptake and negative impact on CD80, CD86, and
CD40 expressions. This phenomenon can be explained by
the upregulation of MHC-II molecules on BMDCs after
exposure to A0C16 liposomes. Surprisingly, OVA-A0C18
liposomes also moderately enhanced T cell activation
although the amount of antigen uptake by APCs was
similar to that of free OVA and the expressions of MHC
and co-stimulatory molecules were partially suppressed.
There is a possibility that the interaction of liposomes
with intracellular organelles, for example, lysosome desta-
bilization, facilitated the antigen processing in BMDCs as
discussed above.21 It should be noted that although some
naked arginine-containing cationic liposomes have
shielded some activation markers on BMDCs, OVA-
loaded liposomes signiﬁcantly increased T cell activation
and proliferation as ﬁnal outcomes, indicating their pre-
dominant contribution to antigen presentation (See the
summary of Figures in Tables S2 and S3).
In consistent with lysine-based cationic liposomes,
the size (80–200 nm) and zeta potential (40–60 mV)
of arginine-based cationic liposomes were not the key
factors that determine their reactivity with the immune
cells; instead, the chemical structures of the hydropho-
bic tails greatly contributed to the NLRP3 inﬂamma-
some activation and the promotion of antigen
presentation by APCs for T cell activation. However,
in comparison to lysine-based liposomes, A3C14
showed more improved antigen delivery efﬁcacy to
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BMDCs than L3C14 bearing the same spacer and
hydrophobic moiety in terms of T cell activation
(approximately ten-fold in IL-2 secretion and two-
fold in D.I. of those of L3C14 in both OT-I and OT-
II cells, Figure S9A and B). Although their NLRP3
inﬂammasome activation potencies were similar,6
A3C14 were found to outweigh L3C14 in OVA deliv-
ery to BMDCs (Figure S9C). It was also reported that
A3C14 were more potent than L3C14 in plasmid DNA
delivery.3 Therefore, arginine-based liposomes were
thought to be superior to lysine-based liposomes for
the application as an immune adjuvant. Further inves-
tigation on how the structure gives an impact on the
bioactivity of the liposomes is necessary for better
understanding of the phenomenon, for example,
whether the spacer or the two-tailed hydrophobic part
of the lipids regulate the fusion potential with plasma
membrane that causes lysosome rupture.
Unlike conventional vaccine adjuvants such as alum,
which is toxic and has a long-lasting cellular exposure,23
A3C14 liposomes are easy to be metabolized owing to the
hydrolytic properties of the composing lipids, and they did
not show signiﬁcant cytotoxicity in vitro when the con-
centration was less than 100 μM. Another advantage of
A3C14 liposomes is the high potential to activate CTLs
through MHC-I mediated antigen presentation, of which
conventional adjuvants often lacks in anticancer
treatment.24,25 Therefore, in the future, in vivo investiga-
tions are expected to validate the adjuvanticity and to
study other immune effects that may be elicited by
A3C14 liposomes.
Conclusion
The structure of hydrophobic moieties of cationic lipids is
crucial for liposome-immune cell interaction. Slight varia-
tion of the alkyl chains could lead to different biological
outcomes of the liposomes or the loaded cargos, eg,
NLRP3 inﬂammasome activation and antigen presentation.
Among all the tested arginine-based cationic liposomes,
A3C14, bearing propyl spacers (C3) between the arginine
head group and ditetradecyl tails (C14) exhibited the stron-
gest NLRP3 inﬂammasome activation and promotion of
both MHC class I- and class II-mediated antigen presenta-
tions without interfering the MHC and co-stimulatory
molecules. The potent cellular uptake and inducement of
lysosome rupture are proposed as a common mechanism
for arginine-based cationic liposomes in the inﬂammasome
activation and enhanced antigen presentation.
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